Shamoon Ushna, Des Bordes Jude K, Goldstein Shira
Department of Family and Community Medicine, University of Texas Health Science Center at Houston McGovern Medical School, Houston, USA.
Cureus. 2024 Apr 2;16(4):e57473. doi: 10.7759/cureus.57473. eCollection 2024 Apr.
Adult attention-deficit/hyperactivity disorder (ADHD) represents a significant public health burden. ADHD is often comorbid with many other psychiatric disorders, with a high co-occurrence with depression. However, there is a paucity in our understanding of the potential impact of treating patients' ADHD on their depressive symptoms. The primary objective of this study was to assess the effect of treating adult ADHD on comorbid depressive symptoms without directly administering treatment for depression in an integrated behavioral health clinic in the primary care setting.
We performed a retrospective chart review between April 2021 and May 2022 on adult patients treated in the Primary Care Adult Integrated Behavioral Health Clinic at an urban family medicine residency clinic. For patients with ADHD, we administered the Adult ADHD Self-Report Scale (ASRS-v1.1) to serve as a marker of ADHD symptom burden and the nine-item Patient Health Questionnaire (PHQ-9) to serve as a marker of depressive symptom burden. We administered the questionnaires prior to initiating ADHD treatment and again at the three-month follow-up visit. The ADHD treatment included pharmacotherapy and brief psychological interventions targeted at ADHD. We compared the ASRS scores and PHQ-9 scores at baseline and after three months to determine whether ADHD treatment had any impact on PHQ-9 scores.
At baseline, the average ASRS score was 11.3 and the average PHQ-9 score was 8.25. Comparing scores after three months of intervention to the initial scores, our preliminary results demonstrated a trend of improvement in both ASRS and PHQ-9 scores. A total of 75% (n=24/32) of the patients had an improvement in ASRS scores, and 56.7% (n=17/30) of the patients had an improvement in PHQ-9 scores at three months. At three months, there was a decline in PHQ-9 scores with a decrease in ASRS scores following treatment.
Our preliminary results suggest that integrated behavioral health treatment of ADHD using a combination of pharmacological and non-pharmacological interventions may play a role in improving comorbid depressive symptoms.
成人注意力缺陷多动障碍(ADHD)是一项重大的公共卫生负担。ADHD常与许多其他精神障碍共病,与抑郁症的共病率很高。然而,我们对治疗患者的ADHD对其抑郁症状的潜在影响了解不足。本研究的主要目的是在初级保健环境中的综合行为健康诊所,评估治疗成人ADHD对共病抑郁症状的影响,而不直接给予抑郁症治疗。
我们对2021年4月至2022年5月期间在城市家庭医学住院诊所的初级保健成人综合行为健康诊所接受治疗的成年患者进行了回顾性病历审查。对于患有ADHD的患者,我们使用成人ADHD自陈量表(ASRS-v1.1)作为ADHD症状负担的指标,使用九项患者健康问卷(PHQ-9)作为抑郁症状负担的指标。我们在开始ADHD治疗前以及在三个月的随访就诊时再次发放问卷。ADHD治疗包括药物治疗和针对ADHD的简短心理干预。我们比较了基线时和三个月后的ASRS分数和PHQ-9分数,以确定ADHD治疗是否对PHQ-9分数有任何影响。
在基线时,平均ASRS分数为11.3,平均PHQ-9分数为8.25。将干预三个月后的分数与初始分数进行比较,我们的初步结果显示ASRS和PHQ-9分数均有改善趋势。在三个月时,共有75%(n = 24/32)的患者ASRS分数有所改善,56.7%(n = 17/30)的患者PHQ-9分数有所改善。在三个月时,治疗后PHQ-9分数随着ASRS分数的下降而下降。
我们的初步结果表明,使用药物和非药物干预相结合的综合行为健康治疗ADHD可能在改善共病抑郁症状方面发挥作用。